researchers in boston have made potentially ground-breaking discoveries that could lead to the development of new therapies for alzheimer’s disease (ad).
in a
first-of-its-kind study
, researchers at massachusetts general hospital, the harvard t. h. chan school of public health, and beth israel deaconess medical center used whole genome sequencing (wgs) to try and find rare genomic variants associated with ad and found 13 such variants (or mutations).
the study also established new genetic links between ad and synapses, which are the structures that transmit information between neurons, and neuroplasticity, or the ability of neurons to reorganize the brain’s neural network.
the genetic origins of ad have been studied for years and previous studies have uncovered the genes that cause early onset familial ad (the form that runs in families), and the genes that cause the buildup of amyloid plaques in the brain, a distinctive feature of ad. dozens of other ad genes have been identified as well, most of those relating to inflammation in the brain, which increases the risk of developing the devastating neurological condition. but what sets this study apart is the discovery of a genetic link between the loss of synapses and the development of ad which had not been previously identified.